Skip to main content
SpringerLink
Log in

Nicht-muskelinvasives Harnblasenkarzinom

Wirksamkeit der elektromotorischen Medikamentenverteilung

Nonmuscle invasive bladder cancer

Efficacy of electromotive drug administration

  • Evidenzbasierte Medizin
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

BCG:

Bacillus Calmette-Guérin

CIS:

Cacinoma in situ

EMDA:

„Electromotive drug administration“ (elektromotorische Verabreichung von Medikamenten)

MIBC:

„Muscle-invasive bladder cancer“ (muskelinvasives Blasenkarzinom)

MMC:

Mitomycin C

NMIBC:

„Non-muscle-invasive bladder cancer“ (nicht-muskelinvasives Blasenkarzinom)

QoE:

„Quality of evidence“ (Evidenzqualität)

RCT:

„Randomized controlled trial“ (randomisierte kontrollierte Studie)

TURBT:

Transurethrale Resektion eines Blasentumors

Literatur

  1. Babjuk M, Böhle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461

    Article  PubMed  Google Scholar 

  2. Brausi M, Witjes JA, Lamm D et al (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186:2158–2167

    Article  PubMed  Google Scholar 

  3. Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43–51

    Article  PubMed  CAS  Google Scholar 

  4. Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777–782

    Article  PubMed  CAS  Google Scholar 

  5. Di Stasi SM, Valenti M, Verri C et al (2011) Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 12:871–879

    Article  PubMed  CAS  Google Scholar 

  6. Ferlay J, Soerjomataram I, Ervik M et al (2013) Globocan. 2012. Cancer incidence and mortality worldwide. IARC CancerBase, Bd. 11. International Agency for Research on Cancer, Lyon

    Google Scholar 

  7. Jung JH, Gudeloglu A, Kiziloz H et al (2017) Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Cochrane Libr. https://doi.org/10.1002/14651858.cd011864.pub2

    Article  Google Scholar 

  8. Maffezzini M, Campodonico F, Canepa G et al (2014) Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol 73:925–930

    Article  PubMed  CAS  Google Scholar 

  9. Shang PF, Kwong J, Wang ZP et al (2008) Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 5. https://doi.org/10.1002/14651858.cd006885

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Fakultät, Klinik für Urologie, Universitätsklinikum Freiburg, Hugstetterstr. 55, 79106, Freiburg, Deutschland

    Arkadiusz Miernik FEBU

  2. UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstraße 8/9, 10709, Berlin, Deutschland

    Arkadiusz Miernik FEBU

Authors
  1. Arkadiusz Miernik FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arkadiusz Miernik FEBU.

Ethics declarations

Interessenkonflikt

A. Miernik ist Mitglied von UroEvidence bei der Deutschen Gesellschaft für Urologie und gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Die Zusammenfassung ist eine Übersetzung des Abstracts der Originalpublikation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miernik, A. Nicht-muskelinvasives Harnblasenkarzinom. Urologe 57, 1133–1136 (2018). https://doi.org/10.1007/s00120-018-0737-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-018-0737-9

Search

Navigation